The global branded generics market is poised for substantial expansion, with its valuation expected to surge from approximately USD 327.8 million in 2023 to an impressive USD 747.2 million by 2033. This significant growth, translating to an 8.6% compound annual growth rate (CAGR), highlights a dynamic upward trend driven by evolving industry conditions and key market drivers.
The accelerating demand for branded generics is predominantly fueled by several pivotal factors. A major influence is the expiration of patents that previously granted exclusive market rights to original drug manufacturers. As these patents lapse, branded generics emerge as viable alternatives, offering high-quality yet more affordable options to consumers. This shift is further supported by increasing government initiatives aimed at raising public awareness and improving access to cost-effective pharmaceutical solutions.
The market’s expansion is also driven by considerable advancements in research and development. Ongoing innovation and increased investment in R&D are essential for enhancing healthcare infrastructure, especially in emerging economies. These technological advancements are creating new opportunities and accelerating the demand for branded generics. Future market growth is anticipated to be supported by sustained R&D efforts and continued technological breakthroughs.
Regionally, North America continues to hold a significant share of the branded generics market, thanks to its advanced healthcare facilities and well-established infrastructure. However, the Asia Pacific region is expected to witness the most rapid growth. This anticipated surge is attributed to the rising demand for affordable pharmaceutical products and increased government support aimed at enhancing healthcare accessibility.
As the branded generics market continues to evolve, stakeholders and industry players are poised to benefit from this robust growth trajectory, driven by a combination of patent expirations, technological advancements, and regional shifts in demand.
Key regional projections include:
- China Projected to expand at a CAGR of 10.4% from 2023 to 2033.
- India Anticipated to grow at an impressive CAGR of 11.9% during the forecast period.
- Australia Expected to expand at a CAGR of 7.5%.
- United States Forecasted to increase its market share by 16.8% between 2023 and 2033.
- Germany Expected to hold a market share of 2.9%.
- Japan Projected to capture a 4.4% market share.
- United Kingdom Likely to register a 9.5% CAGR.
Market Segmentation and Key Takeaways:
The branded generics market is segmented by therapeutic application, drug class, formulation type, and distribution channel:
- Anti-Hypertensive Drugs: Leading the drug class category with a 27.5% revenue share in 2023.
- Cardiovascular Diseases: Expected to dominate the therapeutic application category, with a projected market share of 17.95% by 2033.
- Retail Pharmacy: Accounted for a substantial 43.7% of the distribution channel segment in 2023.
Competitive Landscape and Recent Developments:
The branded generics market is highly competitive, with numerous manufacturers entering the space. Notable recent developments include:
- Acquisition: In July 2021, Lupin acquired Southern Cross Pharma Pty Ltd, enhancing its presence in the branded generics market.
- Product Launch: Dr. Reddy’s Laboratories introduced Invista in India, a branded generic version of Sprycel, in April 2020. Teva Pharmaceuticals and Hikma Pharmaceuticals released a generic version of Tracleer in the U.S. in June 2019.
Elevated Demand for Branded Generics: Our Full Report Offers a Thorough Analysis of Trends and Insights!
Key Players:
Prominent manufacturers in the branded generics market include:
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Novartis
- Mylan
- Pfizer
Branded Generics Market by Category Therapeutic Application:
- Oncology
- Cardiovascular Diseases
- Diabetes
- Neurology
- Gastrointestinal Diseases
- Dermatology Diseases
- Analgesics and Anti-inflammatory
- Others
Drug Class:
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants
- Anti-Psychotics
- Anti-Epileptics
- Others
Formulation Type:
- Oral
- Parenteral
- Topical
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube